Search Resources (English): Adverse drug effect
Results
- Canada's adverse drug reaction database
- Published: 1965-2004
Provides a searchable database that holds information from all adverse drug reaction (ADR) reports currently held in Health Canada's CADRIS (Canadian Adverse Drug Reaction Information System) database, which monitors adverse drug reactions in drugs approved for the Canadian market.
- Canadian adverse reaction newsletter
Provides a newsletter that contains adverse reaction information and is published quarterly, in January, April, July and October of each year. Alerts health professionals to potential signals detected through the review of case reports submitted to Health Canada, and also disseminates information on suspected adverse reactions to health products occurring in humans before comprehensive risk-benefit evaluations and regulatory decisions are undertaken.
- Important safety concerns on the use of Diane-35
- http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/diane-35_hpc-cps-eng.pdf
- Published: 2002
Discusses an article regarding important safety concerns on the use of cyproterone acetate (marketed as Diane-35 in Canada, and as Dianette in the United Kingdom).
(See Details) - Keeping tabs on drug reactions
- http://www.cwhn.ca/resources/drugs/reactions.html
- Explains why PharmaWatch and Women and Health Protection are calling on Health Canada to establish a more effective system for reporting and monitoring adverse drug reactions. (See Details)Published: 2004
- Synthesising licensing data to assess drug safety
- http://bmj.bmjjournals.com/cgi/content/full/328/7438/518
- Argues that if trials done by pharmaceutical companies for licensing purposes had to include adequate data on harms and ineffectiveness the medical community could learn much more quickly what they need to know about new drugs. Contends that the risks of hormone replacement therapy would have been revealed much earlier if better use had been made of existing evidence, and as such, women have been needlessly exposed to an increased risk of heart disease. (See Details)Published: 2004
- Estrogen and breast cancer: a warning to women
- Chronicles the sixty-year attempt to "cure" menopause with female hormones and the forty-year history of chemical contraception. Details the list of medical and epidemiological studies that show estrogen to be a potential carcinogen.Published: 1993
- A hard pill to swallow
- http://www.cbc.ca/consumers/market/files/health/diane/index.html#
- Examines the health risks associated with Diane-35, a drug to treat severe acne, yet marketed as a bill control pill. (See Details)Published: 2005
- Reporting harm caused by medicines
- http://www.whp-apsf.ca/en/documents/adrReport.html
- Discusses why women should report all cases of known or suspected harm from prescription drugs and medicines. Provides contact information for consumers who wish to file a report. (See Details)Published: 2005
- Post-market surveillance of therapeutic drugs in Canada
- http://www.whp-apsf.ca/en/documents/adrBackground.html
- Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)Published: 2005
- The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns
- http://www.cmaj.ca/cgi/content/full/174/2/164
- Reviews the Evra patch and the potential for excess estrogen exposure raises concerns about the risks of adverse effects, which include nausea, breast tenderness and venous thromboembolism. (See Details)Published: 2006
The Canadian Women's Health Network and the Centres of Excellence for Women's Health program are financially supported by Health Canada through the Women's Health Contribution Program. The views herein do not necessarily represent the official policy of Health Canada.